LIXTE Biotechnology Holdings (NASDAQ: LIXT) reported first-quarter 2026 progress in its oncology pipeline, highlighted by the expansion of its ovarian cancer trial for lead candidate LB-100 following favorable safety findings in combination with immunotherapy. The company filed its Form 10-Q, detailing continued development of LB-100, a first-in-class PP2A inhibitor, and strategic growth at its recently acquired Liora Technologies Europe subsidiary.
The ovarian cancer trial expansion reflects LIXTE's commitment to advancing LB-100, which has shown tolerability in cancer patients at doses associated with anti-cancer activity. Based on published preclinical data, LB-100 has the potential to enhance chemotherapies and immunotherapies, offering a new treatment paradigm through a novel approach termed "activation lethality." The company's pipeline also includes trials for metastatic colon cancer and advanced soft tissue sarcoma.
LIXTE's strategic expansion aims to strengthen its oncology pipeline and treatment development capabilities. The Liora Technologies Europe subsidiary, acquired to broaden the company's med-tech footprint, continues to grow. Liora is developing the LiGHT System, an electronically controlled proton therapy system for treating tumors, which is believed to offer advantages over current proton therapy technologies. This diversification positions LIXTE to address multiple facets of cancer treatment, from drug development to advanced radiation therapy.
Investors can access the full press release and additional updates via the company's newsroom at https://ibn.fm/LIXT. LIXTE's leadership emphasizes that the first-quarter results validate the company's direction, with both the pharmaceutical and med-tech divisions contributing to its long-term vision. The company's comprehensive patent portfolio protects its novel cancer biology approach, and ongoing proof-of-concept clinical trials are expected to generate further data on LB-100's efficacy.
As a clinical-stage pharmaceutical and med-tech company, LIXTE Biotechnology Holdings, Inc. focuses on new targets for cancer drug development and commercialization. Its lead compound, LB-100, represents a pioneering effort in activation lethality, an entirely new field of cancer biology. The company's subsidiary, Liora Technologies Europe Ltd., is advancing the LiGHT System, which could significantly improve proton therapy for various cancers. More information about LIXTE can be found at www.lixte.com, and about Liora at www.lioratechnologies.com.
The strategic expansion and pipeline progress underscore LIXTE's commitment to addressing unmet needs in oncology. With the ovarian cancer trial expansion and continued growth of Liora, the company is poised to deliver innovative solutions that could improve outcomes for cancer patients. The first-quarter report reflects steady advancement toward these goals, with further updates expected as trials progress.
